May 24, 2013 - LifeVest Wearable Defibrillator To Be Showcased at European Society of Cardiology Heart Failure Congress 2013

MEDIA CONTACT:  

Diane Egan
ZOLL Medical Corporation
+1 (978) 421-9637
degan@zoll.com  

 

ZOLL LIFEVEST WEARABLE DEFIBRILLATOR TO BE SHOWCASED AT EUROPEAN SOCIETY OF CARDIOLOGY HEART FAILURE CONGRESS 2013

May 24, 2013—CHELMSFORD, MASS.—ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that it will display the LifeVest® Wearable Defibrillator in Booth D10 at the European Society of Cardiology Heart Failure Congress 2013 from 25-28 May in Lisbon, Portugal.

The LifeVest will be discussed during a scientific presentation entitled, “Wearable Cardioverter Defibrillator Use in Patients with Chemotherapy-induced Cardiotoxicity,” presented by Nicole Bianco, PhD, ZOLL Pittsburgh, on Sunday, 26 May, at 2:00 p.m., Poster Session 2, #P1010.

Heart failure affects an estimated 15 million people in Europe. Patients with heart failure are at high risk of sudden cardiac arrest (SCA), especially immediately following an acute event such as hospitalization for heart failure decompensation or myocardial infarction.

The LifeVest is worn by patients at risk for SCA, including patients with cardiomyopathy or congestive heart failure that places them at particular risk. The LifeVest provides protection during their changing condition and while permanent SCA risk has not been established, allowing a patient’s physician time to assess his or her long-term arrhythmic risk and make appropriate plans.

The LifeVest is lightweight and easy to wear, allowing patients to return to their activities of daily living, while having the peace of mind that they are protected from SCA. The LifeVest continuously monitors the patient’s heart and, if a life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm.

The LifeVest is used for a wide range of patient conditions or situations, including following a heart attack, and before or after bypass surgery or stent placement, as well as cardiomyopathy or congestive heart failure that places patients at particular risk.

About ZOLL Medical Corporation

ZOLL Medical Corporation, an Asahi Kasei Group company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care. For more information, visit www.zoll.com.

About Asahi Kasei

The Asahi Kasei Group is a diversified group of companies led by holding company Asahi Kasei Corp., with operations in the chemicals and fibers, homes and construction materials, electronics, and health care business sectors. Its health care operations include devices and systems for critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals, diagnostic reagents, and nutritional products. With more than 25,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries. For more information, visit www.asahi-kasei.co.jp/asahi/en/.

Copyright © 2013 ZOLL Medical Corporation. All rights reserved. LifeVest and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries. Asahi Kasei is a registered trademark of Asahi Kasei Corporation. All trademarks are the property of their respective owners.